## **Supplementary Online Content**

Admon AJ, Iwashyna TJ, Kamphuis LA, et al; National Heart, Lung, and Blood Institute PETAL Network. Assessment of symptom, disability, and financial trajectories in patients hospitalized for COVID-19 at 6 months. *JAMA Netw Open*. 2023;6(2):e2255795. doi:10.1001/jamanetworkopen.2022.55795

- eTable 1. Missingness by Variable
- eTable 2. Participant Demographic Characteristics
- eTable 3. Participant Demographics by Follow-up Status
- eTable 4. Presence of Symptoms at 6 Months by Initial Illness Severity and Comorbidity Status
- **eTable 5.** New or Worsened Cardiopulmonary Symptoms Over Time Compared to Pre-COVID Baseline Among Only Participants Responding to Each of Three Surveys
- **eTable 6.** New or Worsened Cardiopulmonary Symptoms Over Time Compared to Pre-COVID Baseline Restricted Only to Respondents With Three or More Comorbidities at Baseline (n=99)
- **eTable 7.** New or Worsened Cardiopulmonary Symptoms Over Time Compared to Pre-COVID Baseline Restricted to Respondents Who Received Mechanical Ventilation
- eTable 8. Predictors of New Cardiopulmonary Symptoms at 6 Months
- **eTable 9.** Financial Problems at Each Timepoint Among Only Participants Completing All Three Surveys
- eTable 10. Predictors of Any Financial Toxicity at 6 Months
- **eFigure 1.** CONSORT Diagrams—Month 1
- **eFigure 2.** CONSORT Diagrams—Month 3
- eFigure 3. CONSORT Diagrams—Month 6
- eFigure 4. Trajectories in Perceived Recovery Over Time
- **eFigure 5.** Trajectories in Self-reported Fatigue
- eAppendix. List of BLUE CORAL Investigators

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1: Missingness by variable

| erable 1: Missingness by Variable   |          |              |
|---|----------|--------------|
| Variable  | Number   | Percent      |
|   | Missing  | Missing      |
| Financial Problems  |          |              |
| Used up all or most of savings  | 36       | 1.8%         |
| Were unable to pay for necessities  | 30       | 1.5%         |
| Were contacted by a collection agency   | 36       | 1.8%         |
| Declared bankruptcy   | 34       | 1.7%         |
| Skipped or delayed medical care because of cost   | 30       | 1.5%         |
| Took less medications because of the cost   | 32       | 1.6%         |
| Lost a job  | 21       | 1.1%         |
| Had to change work  | 29       | 1.5%         |
| Had a loved one take time off of work   | 27       | 1.4%         |
| Been told that insurance would not cover therapy or rehab                                 | 40       | 2.0%         |
| Been told that insurance would not cover equipment  | 41       | 2.1%         |
| How much of a drain on your family's financial resources                                  | 36       | 1.8%         |
| Tiow made of a drain on your family o infamiliar resources                                | 00       | 1.070        |
| Symptoms  |          |              |
| Cough   | 33       | 1.7%         |
| Chest trouble with smells/fumes   | 41       | 2.1%         |
| Breathlessness with sleep   | 38       | 1.9%         |
| Chest trouble when upset  | 37       | 1.9%         |
| Chest trouble when upset  Chest trouble getting around the house                          | 36       | 1.8%         |
| Chest trouble leads to going home early   | 36<br>42 | 2.1%         |
| Breathlessness when laughing  | 42       | 2.1%         |
| 5 5   | _        | 2.0%<br>1.7% |
| Using home oxygen   | 33<br>37 | 1.7%         |
| Using CPAP or another breathing machine during sleep<br>Swelling in feet, ankles, or legs | 57<br>52 | 2.7%         |
|   | -        |              |
| Breathlessness when lying flat  | 43       | 2.2%         |
| Rapid or irregular heartbeat  | 57       | 2.9%         |
| Chest pain, tightness, or angina  | 47       | 2.4%         |
| ADL/IADL deficits versus enrollment   | 7        | 0.4%         |
| Feeling tired or having little energy   | 140      | 7.1%         |
| Quality of Life (EQ-5D-5L)  |          |              |
| Anxiety/Depression  | 12       | 0.6%         |
| Mobility  | 5        | 0.3%         |
| Pain/Discomfort   | 8        | 0.4%         |
| Self-care   | 8        | 0.4%         |
| Usual activities  | 11       | 0.6%         |
| Demographics  |          |              |
| <del>-</del> •  | 0        | 0.0%         |
| Race/Ethnicity  | 0        |              |
| Medicare Beneficiary  | 8        | 0.4%         |
| Primary Language  | 3        | 0.2%         |
| Severity of Illness   |          |              |
| Charlson comorbidities  | 0        | 0.0%         |
| Discharge disposition   |          |              |
| Immunosuppressed status   | 0        | 0.0%         |
| Hospital length of stay   | 0        | 0.0%         |
| Highest level of care   | 0        | 0.0%         |
| Maximal oxygen use  | 0        | 0.0%         |
| Vasopressors  | 0        | 0.0%         |
|   |          |              |

CPAP: continuous positive airway pressure; EQ-5D-5L: European Quality of Life five-dimension five-level instrument © 2023 Admon AJ et al. *JAMA Network Open*.

eTable 2: Participant demographic characteristics (n=825)

| Characteristic                  | No. (%)     |
|---------------------------------|-------------|
| Age, median (IQR), y            | 56 (43, 66) |
| Age, categorical, y             |             |
| ≤ 50                            | 313 (38.9)  |
| 51-60                           | 169 (21.0)  |
| 61-70                           | 191 (23.7)  |
| 71-80                           | 87 (10.8)   |
| ≥ 81                            | 45 (5.6)    |
| Sex                             |             |
| Male                            | 444 (54.0)  |
| Female                          | 379 (46.1)  |
| Race                            |             |
| Hispanic                        | 253 (30.7)  |
| Non-Hispanic Black or African   | , ,         |
| American                        | 145 (17.6)  |
| Non-Hispanic White              | 360 (43.6)  |
| Other or Unknown*               | 67 (8.1)    |
| Primary Language                | ` '         |
| English                         | 717 (86.9)  |
| Spanish                         | 108 (13.1)  |
| Charlson Comorbidities          | , ,         |
| None                            | 444 (53.8)  |
| 1                               | 186 (22.6)  |
| 2                               | 96 (11.6)   |
| 3 or more                       | 99 (12.0)   |
| Immunocompromised               | 123 (14.9)  |
| Highest Level of Care           |             |
| Ward                            | 540 (65.5)  |
| Intermediate or stepdown        | 185 (22.4)  |
| Intensive care unit             | 100 (12.1)  |
| Maximal oxygen support          |             |
| None                            | 134 (16.2)  |
| Conventional oxygen             | 441 (53.5)  |
| High flow nasal cannula         | 131 (15.9)  |
| Non-invasive ventilation        | 43 (5.2)    |
| Invasive mechanical ventilation | 76 (9.2)    |
| Vasopressor Use                 | 71 (8.6)    |
| Length of stay, median (IQR), d | 6 (4, 10)   |
| Hospital discharge              |             |
| location**                      |             |
| Home independently              | 640 (77.6)  |
| Home with help                  | 120 (14.6)  |
| To another facility             | 65 (7.9)    |
| •                               | , ,         |

<sup>\*</sup>Includes American Indian/Alaskan Native, Asian, Native Hawaiian/Pacific Islander, other/declined, and unknown.

<sup>\*\*</sup>Home discharge without services includes discharge against medical advice and discharge to a COVID Hotel or similar non-healthcare facility.

eTable 3: Participant demographic by follow-up status

| Characteristic                            | Completed only<br>Month 1 (n=84) | Completed Months 1, 3, and 6 (n=473) | <i>P</i> Value <sup>†</sup> |
|---|----------------------------------|--------------------------------------|-----------------------------|
| Age, median (IQR), y                      | 51 (38, 65)                      | 59 (47, 68)                          | <0.001                      |
| Age, categorical, y                       |                                  |                                      | 0.005                       |
| ≤ 50                                      | 38 (46.9%)                       | 143 (31.0%)                          |                             |
| 51-60                                     | 17 (21.0%)                       | 105 (22.7%)                          |                             |
| 61-70                                     | 22 (27.2%)                       | 123 (26.6%)                          |                             |
| ≥71                                       | 4 (4.9%)                         | 91 (18.7%)                           |                             |
| Sex                                       |                                  |                                      | 0.87                        |
| Male                                      | 40 (47.6%)                       | 230 (48.6%)                          |                             |
| Female                                    | 44 (52.4%)                       | 243 (51.4%)                          |                             |
| Race                                      |                                  |                                      | 0.14                        |
| Hispanic                                  | 31 (38.1%)                       | 127 (26.9%)                          |                             |
| Non-Hispanic Black or African<br>American | 11 (13.1%)                       | 87 (18.4%)                           |                             |
| - Non-Hispanic White                      | 34 (40.5%)                       | 227 (48.0%)                          |                             |
| Other or Unknown*                         | 7 (8.3%)                         | 32 (6.8%)                            |                             |
| Primary Language                          | ,                                | ,                                    | 0.61                        |
| English                                   | 72 (85.7%)                       | 415 (87.7%)                          |                             |
| Spanish                                   | 12 (14.3%)                       | 58 (13.3%)                           |                             |
| Charlson Comorbidities                    | ,                                | ,                                    | 0.12                        |
| None                                      | 52 (61.9%)                       | 241 (51.0%)                          |                             |
| 1   | 12 (14.3%)                       | 121 (25.6%)                          |                             |
| 2   | 11 (13.1%)                       | 53 (11.2%)                           |                             |
| 3 or more                                 | 9 (10.7%)                        | 58 (12.3%)                           |                             |
| Immunocompromised                         | 12 (14.3%)                       | 72 (15.2%)                           | 0.83                        |
| Highest Level of Care                     | ,                                | ,                                    | 0.52                        |
| Ward                                      | 60 (71.4%)                       | 309 (65.3%)                          |                             |
| Intermediate or stepdown                  | 16 (19.1%)                       | 103 (21.8%)                          |                             |
| Intensive care unit                       | 8 (9.5%)                         | 61 (12.9%)                           |                             |
| Maximal oxygen support                    | ,                                | ,                                    | 0.26                        |
| None                                      | 20 (23.8%)                       | 68 (14.4%)                           |                             |
| Conventional oxygen                       | 42 (50.0%)                       | 257 (54.3%)                          |                             |
| High flow nasal cannula                   | 12 (14.3%)                       | 79 (16.7%)                           |                             |
| Non-invasive ventilation                  | 3 (3.6%)                         | 28 (5.9%)                            |                             |
| Invasive mechanical ventilation           | 7 (8.3%)                         | 41 (8.7%)                            |                             |
| Vasopressor Use                           | 10 (11.9%)                       | 35 (7.4%)                            | 0.16                        |
| Length of stay, median (IQR), d           | 5 (3, 8)                         | 5 (3, 9)                             | 0.09                        |
| Hospital discharge location**             | 3 (3, 3)                         | 3 (3, 3)                             | 0.48                        |
| Home independently                        | 68 (81.0%)                       | 354 (74.8%)                          | 3.10                        |
| Home with help                            | 11 (13.1%)                       | 79 (16.7%)                           |                             |
| To another facility                       | 5 (6.0%)                         | 40 (8.5%)                            |                             |
| To another facility                       | J (U.U /U)                       | -to (0.070)                          |                             |

<sup>\*</sup>Includes American Indian/Alaskan Native, Asian, Native Hawaiian/Pacific Islander, other/declined, and unknown.

<sup>\*\*</sup>Home discharge without services includes discharge against medical advice and discharge to a COVID Hotel or similar non-healthcare facility.

<sup>&</sup>lt;sup>†</sup>Using Wilcoxon rank-sum test for continuous variables and chi-squared test for categorical variables.

eTable 4: Presence of symptoms at 6 months by initial illness severity and comorbidity status.

|  | All participants at 6 months (n=641) | - · · · · · | ICU<br>(n=82)              | comorbidities |         | comorbidities | Diabetes<br>Mellitus       | Chronic<br>Lung<br>Disease<br>(n=45) |
|--|--------------------------------------|-------------|----------------------------|---------------|---------|---------------|----------------------------|--------------------------------------|
| Any cardiorespiratory symptom at 6 months            | (71.9%,                              | (71.6%,     | 76.8%<br>(66.2%,<br>85.4%) | (66.8%,       | (74.2%, | (71.3%,       | (73.5%,                    | 88.9%<br>(76.0%,<br>96.3%)           |
| Any financial problem at 6 months                    | (52.5%,                              | (52.7%,     | (36.4%,                    | (46.1%,       | (55.8%, | (42.9%,       | 61.9%<br>(54.8%,<br>68.7%) | 62.2%<br>(46.5%,<br>76.2%)           |
| At least 1 new<br>ADL/IADL impairment<br>at 6 months | (43.3%,                              | (39.4%,     | (30.0%,                    | (35.6%,       | (48.3%, | (40.5%,       | 52.3%<br>(45.1%,<br>59.4%) | 62.2%<br>(46.5%,<br>76.2%)           |
| Less than 100% of baseline health at 6 months        | (68.2%,                              | (66.1%,     | 66.7%<br>(55.3%,<br>76.8%) | ,             | (68.7%, | (63.6%,       | (64.9%,                    | 68.9%<br>(53.4%,<br>81.8%)           |

ADL: Activity of daily living; IADL: Instrumental activity of daily living

**eTable 5**: New or worsened cardiopulmonary symptoms over time compared to pre-COVID baseline among only participants responding to each of three surveys (n=473 participants)

|   | Surv    | Survey Timepoint (%) |         |          |
|---|---------|----------------------|---------|----------|
|   | Month 1 | Month 3              | Month 6 | P Value* |
| Symptoms                                  |         |                      |         |          |
| Chest trouble with odors/fumes            | 13.58   | 30.54                | 29.85   | <0.001   |
| Cough                                     | 20.82   | 21.79                | 27.72   | 0.006    |
| Swelling in feet, ankles, or legs         | 10.99   | 22.48                | 24.78   | <0.001   |
| Chest trouble when upset                  | 16.81   | 26.55                | 24.52   | <0.001   |
| Rapid or irregular heartbeat              | 19.52   | 21.43                | 20.00   | 0.82     |
| Breathlessness with sleep                 | 14.19   | 19.91                | 21.87   | <0.001   |
| Chest pain, tightness, or angina          | 14.87   | 19.23                | 18.75   | 0.06     |
| Breathlessness when laughing              | 18.24   | 17.09                | 17.95   | 0.89     |
| Breathlessness when lying flat            | 12.90   | 13.68                | 13.95   | 0.57     |
| Chest trouble getting around the house    | 15.91   | 15.42                | 16.14   | 0.91     |
| Chest trouble leads to going home early   | 15.09   | 16.03                | 15.07   | 0.99     |
| Any symptom                               | 53.78   | 64.73                | 64.68   | <0.001   |
| CPAP and supplemental oxygen              |         |                      |         |          |
| Using CPAP or another breathing           |         |                      |         |          |
| machine during sleep                      | 5.64    | 13.43                | 15.07   | <0.001   |
| Using home oxygen                         | 21.20   | 15.35                | 12.53   | <0.001   |
| Any CPAP or supplemental oxygen           | 23.44   | 23.67                | 23.14   | 0.88     |
| Any symptom, CPAP, or supplemental oxygen | 68.74   | 75.74                | 76.48   | 0.002    |

<sup>\*</sup>P value calculating using Somers' D accounting for clustering of observations by respondent. CPAP: continuous positive airway pressure

**eTable 6:** New or worsened cardiopulmonary symptoms over time compared to pre-COVID baseline restricted only to respondents with three or more comorbidities at baseline (N=99)

|   | Surv    | Survey Timepoint (%) |         |          |
|---|---------|----------------------|---------|----------|
|   | Month 1 | Month 3              | Month 6 | P Value* |
| Symptoms                                  |         |                      |         |          |
| Chest trouble with odors/fumes            | 11.25   | 17.57                | 24.05   | 0.01     |
| Cough                                     | 11.25   | 24.00                | 23.75   | 0.005    |
| Swelling in feet, ankles, or legs         | 8.86    | 23.61                | 23.08   | 0.001    |
| Chest trouble when upset                  | 12.50   | 18.92                | 17.72   | 0.29     |
| Rapid or irregular heartbeat              | 12.66   | 13.70                | 12.99   | 0.94     |
| Breathlessness with sleep                 | 11.25   | 14.67                | 20.99   | 0.08     |
| Chest pain, tightness, or angina          | 8.86    | 13.33                | 11.69   | 0.51     |
| Breathlessness when laughing              | 17.72   | 8.22                 | 12.82   | 0.33     |
| Breathlessness when lying flat            | 10.13   | 10.81                | 16.67   | 0.10     |
| Chest trouble getting around the house    | 15.19   | 17.57                | 16.05   | 0.84     |
| Chest trouble leads to going home early   | 8.97    | 6.76                 | 7.50    | 0.73     |
| Any symptom                               | 43.04   | 63.89                | 61.25   | 0.12     |
| CPAP and supplemental oxygen              |         |                      |         |          |
| Using CPAP or another breathing           |         |                      |         |          |
| machine during sleep                      | 3.85    | 13.33                | 17.50   | <0.001   |
| Using home oxygen                         | 26.58   | 20.00                | 18.75   | 0.17     |
| Any CPAP or supplemental oxygen           | 29.11   | 28.00                | 30.00   | 0.88     |
| Any symptom, CPAP, or supplemental oxygen | 71.25   | 80.00                | 81.48   | 0.006    |

<sup>\*</sup>P value calculating using Somers' D accounting for clustering of observations by respondent. CPAP: continuous positive airway pressure

**eTable 7:** New or worsened cardiopulmonary symptoms over time compared to pre-COVID baseline restricted only to respondents who received mechanical ventilation (N=76)

|   | Surv    | Survey Timepoint (%) |         |          |
|---|---------|----------------------|---------|----------|
|   | Month 1 | Month 3              | Month 6 | P Value* |
| Symptoms                                  |         |                      |         |          |
| Chest trouble with odors/fumes            | 8.93    | 18.97                | 27.78   | 0.005    |
| Cough                                     | 19.30   | 31.58                | 29.63   | 0.12     |
| Swelling in feet, ankles, or legs         | 14.29   | 28.07                | 16.98   | 0.63     |
| Chest trouble when upset                  | 17.86   | 24.56                | 23.64   | 0.38     |
| Rapid or irregular heartbeat              | 16.07   | 19.64                | 26.42   | 0.12     |
| Breathlessness with sleep                 | 12.28   | 17.54                | 23.21   | 0.10     |
| Chest pain, tightness, or angina          | 8.93    | 17.54                | 19.23   | 0.006    |
| Breathlessness when laughing              | 16.07   | 26.32                | 25.93   | 0.15     |
| Breathlessness when lying flat            | 16.07   | 17.86                | 3.70    | 0.001    |
| Chest trouble getting around the house    | 10.71   | 12.73                | 18.18   | 0.15     |
| Chest trouble leads to going home early   | 16.07   | 14.55                | 17.86   | 0.77     |
| Any symptom                               | 50.00   | 73.68                | 62.96   | 0.06     |
| CPAP and supplemental oxygen              |         |                      |         |          |
| Using CPAP or another breathing           |         |                      |         |          |
| machine during sleep                      | 12.28   | 10.34                | 18.18   | 0.28     |
| Using home oxygen                         | 36.84   | 19.30                | 23.64   | 0.05     |
| Any CPAP or supplemental oxygen           | 43.86   | 24.56                | 34.55   | 0.19     |
| Any symptom, CPAP, or supplemental oxygen | 79.31   | 81.36                | 73.21   | 0.41     |

<sup>\*</sup>P value calculating using Somers' D accounting for clustering of observations by respondent. CPAP: continuous positive airway pressure

**eTable 8:** Predictors of new cardiopulmonary symptoms at 6 months (N=523 participants). Model 1 includes demographic characteristics. Model 2 adds pre-hospital comorbidities. Model 3 adds hospital severity of illness. Model 4 adds presence of cardiopulmonary symptoms at 1 month.

| miless. Woder + adds presence of cardiopair         | January Gympte | Odds Ratio (95% CI) |               |               |
|---|----------------|---------------------|---------------|---------------|
|   | Model 1        | Model 2             | Model 3       | Model 4       |
| Age in Decades                                      | 2.28*          | 2.18*               | 2.03          | 1.74          |
| 7.go 2000.000                                       | (1.14, 4.55)   | (1.05 4.52)         | (0.92, 4.45)  | (0.76, 4.02)  |
| Age <sup>2</sup>                                    | 0.94*          | 0.94*               | 0.94          | 0.95          |
| 3   | (0.88, 0.99)   | (0.88 1.00)         | (0.87, 1.01)  | (0.88, 1.03)  |
| Sex (vs. female)                                    | , , ,          | ,                   | ,             | ,             |
| Male  | 0.48**         | 0.48**              | 0.50**        | 0.59*         |
|   | (0.31, 0.76)   | (0.31 0.77)         | (0.32, 0.79)  | (0.37, 0.95)  |
| Race and Ethnicity (vs. non-Hispanic White)         |                |                     |               |               |
| Hispanic  | 1.01           | 0.98                | 0.94          | 1.11          |
|   | (0.66, 1.54)   | (0.65 1.47)         | (0.61, 1.46)  | (0.67, 1.82)  |
| Non-Hispanic Black                                  | 1.22           | 1.19                | 1.22          | 1.62          |
|   | (0.70, 2.12)   | (0.70 2.02)         | (0.71, 2.08)  | (0.94, 2.80)  |
| Other/Unknown <sup>†</sup>                          | 0.61           | 0.56*               | 0.55*         | 0.83          |
|   | (0.36, 1.02)   | (0.32 1.00)         | (0.31, 0.98)  | (0.39, 1.76)  |
| Medicare beneficiary (vs. non-Medicare beneficiary) |                |                     |               |               |
| Yes   | 0.88           | 1.49                | 0.88          | 0.94          |
|   | (0.54, 1.45)   | (0.79 2.81)         | (0.52, 1.47)  | (0.51, 1.72)  |
| Unknown   | 1.49           | 0.86                | 1.62          | 1.67          |
| Number of Obsiders agreed 1885 (1900)               | (0.79, 2.81)   | (0.51 1.43)         | (0.87, 3.03)  | (0.87, 3.21)  |
| Number of Charlson comorbidities (vs. 0)            |                |                     | 4.40          | 4.04          |
| 1   |                | 1.14                | 1.12          | 1.24          |
| 0   |                | (0.66 1.97)         | (0.63, 2.01)  | (0.57, 2.72)  |
| 2   |                | 2.39*               | 2.37*         | 2.13          |
| 2 04 0000   |                | (1.06 5.40)         | (1.08, 5.20)  | (0.83, 5.45)  |
| 3 or more   |                | 1.74                | 1.68          | 1.50          |
|   |                | (0.83 3.64)         | (0.79, 3.59)  | (0.76, 2.96)  |
| Immunocompromised (vs. not immunocompromised)       |                | 0.70                | 0.04          | 4.40          |
| Immunocompromised                                   |                | 0.79                | 0.91          | 1.10          |
| Quartile of Length of Stay (vs. first quartile)     |                | (0.48 1.30)         | (0.55, 1.51)  | (0.66, 1.84)  |
| Second quartile                                     |                |                     | 0.87          | 0.82          |
| Second quartile                                     |                |                     | (0.50, 1.53)  | (0.47, 1.43)  |
| Third quartile                                      |                |                     | 1.59          | 1.29          |
| Tillia quartile                                     |                |                     | (0.89, 2.85)  | (0.76, 2.19)  |
| Fourth (longest) quartile                           |                |                     | 1.37          | 1.18          |
| r ourth (longoot) quartile                          |                |                     | (0.68, 2.75)  | (0.58, 2.38)  |
| Highest Level of Care (vs. ward)                    |                |                     | (0.00, 2.70)  | (0.00, 2.00)  |
| Intermediate or Stepdown                            |                |                     | 0.51          | 0.52          |
|   |                |                     | (0.22, 1.16)  | (0.20, 1.33)  |
| ICU   |                |                     | 0.84          | 0.84          |
|   |                |                     | (0.42, 1.68)  | (0.34, 2.07)  |
| Maximal oxygen device (vs. none)                    |                |                     | (- ,,         | (,,           |
| Conventional Oxygen                                 |                |                     | 1.83*         | 1.71*         |
| 7.0   |                |                     | (1.13, 2.97)  | (1.10, 2.66)  |
| High Flow Nasal Cannula                             |                |                     | 1.95          | 1.74          |
|   |                |                     | (0.89, 4.26)  | (0.76, 3.95)  |
| Non-invasive Positive Pressure Ventilation          |                |                     | 3.54          | 2.49          |
|   |                |                     | (0.99, 12.63) | (0.63, 9.85)  |
| Mechanical Ventilation                              |                |                     | 1.54          | 1.73          |
|   |                |                     | (0.28, 8.63)  | (0.22, 13.76) |
| Vasopressors (vs no vasopressors)                   |                |                     |               |               |
| Received Vasopressors                               |                |                     | 1.72          | 1.01          |
|   |                |                     | (0.77, 3.87)  | (0.30, 3.40)  |
| Cardiorespiratory symptoms at 1 month (vs. no       |                |                     |               |               |
| symptoms)   |                |                     |               |               |
| Yes   |                |                     |               | 3.25***       |
|   |                |                     |               | (2.01, 5.27)  |
| Intercept   | 0.45           | 0.50                | 0.36          | 0.22          |
|   | (0.06, 3.24)   | (0.06 3.92)         | (0.04, 2.97)  | (0.02, 2.24)  |
| AUROC   | 0.625          | 0.643               | 0.677         | 0.721         |
| *** p = 001 ** p = 01 * p = 05                      |                |                     |               |               |

<sup>\*\*\*</sup> p<.001, \*\* p<.01, \* p<.05,

<sup>&</sup>lt;sup>†</sup>Includes American Indian/Alaskan Native, Asian, Native Hawaiian/Pacific Islander, other/declined, and unknown ICU: intensive care unit; AUROC: area under the receiver operating characteristic curve

**eTable 9**: Financial problems at each timepoint among only participants responding to each of three surveys (n=473 participants)

|  | Surve   | Survey Timepoint (%) |         |          |
|--|---------|----------------------|---------|----------|
|  | Month 1 | Month 3              | Month 6 | P Value* |
| At any time because of COVID hospitalization, have you     |         |                      |         |          |
| used up all or most of savings?                            | 29.21   | 31.26                | 33.40   | 0.05     |
| been unable to pay for necessities?                        | 17.48   | 18.55                | 19.40   | 0.33     |
| been contacted by a collection agency?                     | 10.23   | 11.99                | 16.70   | < 0.001  |
| skipped or delayed medical care because of cost?           | 7.46    | 8.49                 | 8.32    | 0.51     |
| taken less medications because of the cost?                | 4.90    | 6.61                 | 6.40    | 0.25     |
| declared bankruptcy?                                       | 0.85    | 1.28                 | 1.50    | 0.35     |
| Since our last contact, have you                           |         |                      |         |          |
| had a loved one take time off of work?                     | 38.54   | 23.62                | 20.51   | < 0.001  |
| had to change work?  | 13.25   | 14.07                | 10.59   | 0.13     |
| been told that insurance would not cover therapy or rehab? | 3.85    | 5.59                 | 6.17    | 0.06     |
| lost a job?  | 7.46    | 6.57                 | 6.34    | 0.42     |
| been told that insurance would not cover equipment?        | 6.42    | 5.59                 | 4.71    | 0.17     |
| Prevalence of any financial problem                        | 63.83   | 56.36                | 53.70   | <0.001   |

<sup>\*</sup>P value calculating using Somers' D accounting for clustering of observations by respondent.

eTable 10: Predictors of any financial problems at 6 months (N=528 participants). Model 1 includes demographic characteristics. Model 2 adds pre-hospital comorbidities. Model 3 adds hospital severity of illness. Model 4 adds presence of financial problems at 1 month.


|   | Model 1      | Odds Ratio (9<br>Model 2 | Model 3              |                      |
|---|--------------|--------------------------|----------------------|----------------------|
|   |              |                          | Model 3              | Model 4              |
| Age in Decades  | 1.80         | 1.56                     | 1.51                 | 1.46                 |
|   | (0.90, 3.58) | (0.76 3.20)              | (0.73, 3.12)         | (0.68, 3.13)         |
| Age <sup>2</sup>  | 0.94         | 0.95                     | 0.95                 | 0.96                 |
|   | (0.88, 1.00) | (0.89 1.01)              | (0.89, 1.02)         | (0.90, 1.03)         |
| Sex (vs. female)  |              |                          |                      |                      |
| Male  | 0.80         | 0.82                     | 0.82                 | 0.77                 |
|   | (0.61, 1.06) | (0.61 1.10)              | (0.61, 1.11)         | (0.52, 1.14)         |
| Race and Ethnicity (vs. non-Hispanic White)                     |              |                          |                      |                      |
| Hispanic  | 3.64***      | 3.63***                  | 3.52***              | 3.74***              |
|   | (2.51, 5.27) | (2.50 5.27)              | (2.41, 5.15)         | (2.24, 6.23)         |
| Non-Hispanic Black  | 2.99***      | 2.86***                  | 2.97***              | 2.63***              |
|   | (2.01, 4.44) | (1.94 4.20)              | (2.10, 4.20)         | (1.65, 4.20)         |
| Other/Unknown <sup>†</sup>                                      | 2.66**       | 2.53*                    | 2.47*                | 3.28*                |
|   | (1.28, 5.55) | (1.19 5.41)              | (1.19, 5.12)         | (1.32, 8.17)         |
| Medicare beneficiary (vs. non-Medicare Beneficiary)             |              |                          |                      |                      |
| Yes   | 0.75         | 1.46                     | 0.70                 | 0.89                 |
|   | (0.52, 1.09) | (0.90 2.36)              | (0.48, 1.01)         | (0.53, 1.51)         |
| Unknown   | 1.54         | 0.69*                    | 1.59                 | 1.35                 |
| No of the COL of the control of Process (1000)                  | (0.96, 2.49) | (0.47 1.00)              | (0.90, 2.83)         | (0.68, 2.69)         |
| Number of Charlson comorbidities (vs. 0)                        |              |                          |                      |                      |
| 1   |              | 1.83**                   | 1.84**               | 1.64                 |
|   |              | (1.27 2.64)              | (1.24, 2.74)         | (0.99, 2.73)         |
| 2   |              | 2.08**                   | 2.08**               | 1.68                 |
| •                         |              | (1.34 3.24)              | (1.27, 3.38)         | (0.92, 3.08)         |
| 3 or more   |              | 1.25                     | 1.25                 | 1.27                 |
| 1   |              | (0.83 1.89)              | (0.75, 2.08)         | (0.67, 2.42)         |
| Immunocompromised (vs. not immunocompromised)                   |              | 4.04                     | 4.40                 | 4.40                 |
| Immunocompromised   |              | 1.21                     | 1.19                 | 1.13                 |
| Quartile of Langth of Stoy (va. first quartile)                 |              | (0.79 1.86)              | (0.78, 1.84)         | (0.67, 1.89)         |
| Quartile of Length of Stay (vs. first quartile) Second quartile |              |                          | 1.04                 | 1.01                 |
| Second quartile   |              |                          | 1.04                 | 1.01                 |
| Third quartile  |              |                          | (0.57, 1.87)<br>1.57 | (0.51, 2.00)<br>1.22 |
| Third quartile  |              |                          | (0.84, 2.93)         | (0.64, 2.35)         |
| Fourth (longest) quartile                                       |              |                          | 1.80                 | (0.64, 2.33)         |
| i outili (longest) quartile                                     |              |                          | (0.88, 3.69)         | (0.61, 3.43)         |
| Highest Level of Care (vs. ward)                                |              |                          | (0.00, 3.09)         | (0.01, 3.43)         |
| Intermediate or Stepdown  |              |                          | 0.59                 | 0.58                 |
| intermediate of diepdown  |              |                          | (0.31, 1.12)         | (0.30, 1.14)         |
| ICU   |              |                          | 0.80                 | 0.66                 |
|   |              |                          | (0.42, 1.54)         | (0.35, 1.22)         |
| Maximal oxygen device (vs. none)                                |              |                          | (0=,)                | (0.00, 1.22)         |
| Conventional Oxygen   |              |                          | 0.82                 | 0.70                 |
|   |              |                          | (0.47, 1.43)         | (0.35, 1.41)         |
| High Flow Nasal Cannula   |              |                          | 0.96                 | 0.65                 |
| 9   |              |                          | (0.42, 2.19)         | (0.24, 1.77)         |
| Non-invasive Positive Pressure Ventilation                      |              |                          | 0.80                 | 0.72                 |
|   |              |                          | (0.35, 1.85)         | (0.35, 1.50)         |
| Mechanical Ventilation  |              |                          | 0.55                 | 0.90                 |
|   |              |                          | (0.11, 2.73)         | (0.11, 7.61)         |
| Vasopressors (vs. no vasopressors)                              |              |                          | . , -,               | , , - ,              |
| Received Vasopressors   |              |                          | 2.65                 | 1.11                 |
| ·   |              |                          | (0.69, 10.13)        | (0.20, 6.05)         |
| Financial problems at 1 month (vs. no financial problems)       |              |                          | •                    | ,                    |
| Yes   |              |                          |                      | 8.03***              |
|   |              |                          |                      | (5.12, 12.61)        |
| Intercept   | 0.23         | 0.30                     | 0.36                 | 0.11*                |
|   | (0.04, 1.39) | (0.05 1.89)              | (0.06, 2.36)         | (0.01, 0.92)         |
| AUROC *** >   | 0.692        | 0.707                    | 0.722                | 0.811                |

<sup>\*\*\*</sup> p<.001, \*\* p<.01, \* p<.05


†Includes American Indian/Alaskan Native, Asian, Native Hawaiian/Pacific Islander, other/declined, and unknown.

ICU: intensive care unit; AUROC: area under the receiver operating characteristic curve


eFigure 1: CONSORT Diagram - Month 1




eFigure 2: CONSORT Diagram - Month 3




eFigure 3: CONSORT Diagrams - Month 6



**eFigure 4:** Trajectories in perceived recovery over time. Alluvial diagram displaying perceived recovery (as a percentage of baseline health) of respondents at each timepoint (vertical bars) and changes in responses over time (horizontal lines). Bar and line thicknesses are proportional to the number of patients represented by the relevant category or change.



**eFigure 5:** Trajectories in self-reported fatigue. Alluvial diagram displaying how often a participant reported fatigue over the preceding 14 days (vertical bars) and changes in responses over time (horizontal lines). Bar and line thicknesses are proportional to the number of patients represented by the relevant category or change.



## Complete list of BLUE CORAL Collaborators

Biology and Longitudinal Epidemiology of PETAL COVID-19 Observational Study (BLUE CORAL):

ALIGNE Clinical Center: <u>Baystate Medical Center</u> - Jay Steingrub\*, Mark Tidswell, Lori Kozikowski, Lesley De Souza, Cynthia Kardos, Sarah Romain; <u>Brigham and Women's Hospital</u> - Rebecca M. Baron, Mayra Pinilla, Katherin Zambrano-Vera, Antonio Arciniegas; <u>Maine Medical Center</u> - Richard Riker, Christine Lord, Ashley Eldridge; <u>University of Florida:</u> Marie-Carmelle Elie, Torben K Becker, Matthew Shaw, Christopher J Duncan, Jesseca Antoine

**BOSTON Clinical Center:** Beth Israel Deaconess Medical Center - Daniel Talmor\*, Nathan Shapiro\*, Valerie Banner-Goodspeed, Sharon Hayes, Krystal Capers, Andre de Souza Licht, Lisa Kurt; Massachusetts General Hospital - Kathryn Hibbert, Kelsey Brait, Tatiana Held; University of Mississippi Medical Center - Alan E Jones, **Rebekah Peacock, James W. Galbraith, Utsav Nandi, Jenna L. Davis** 

CALIFORNIA Clinical Center: <u>University of California San Francisco</u> -Michael Matthay\*, Kirsten Kangelaris, Kimberly Yee, Kimia Ashktorab, Rachel Gropper, Anika Agrawal; <u>University of California San Francisco – Fresno</u> -Eyad Almasri, Kinsley Hubel, Mohamed Fayed, Alyssa Hughes, Rebekah Garcia; <u>Stanford University Hospital</u> -Angela Rogers, Jennifer Wilson, Rosemary Vojnik, Jonasel Roque, Cynthia Perez; <u>UCLA Ronald Reagan Medical Center</u> -Nida Qadir, George Lim, Steve Chang, Greg Hendey\*, Rebecca Beutler, Trisha Agarwal, Julia Vargas; <u>University of Texas Health Science</u> <u>Center at Houston</u> -Ryan Huebinger, Bela Patel, Elizabeth Vidales

COLORADO Clinical Center: <u>University of Colorado Hospital</u> -Marc Moss\*, Adit Ginde\*, Neil Aggarwal\*, Jeffrey McKeehan, Carrie Higgins, Lani Finck; <u>Denver Health Medical Center</u> -Jason Haukoos, Ivor Douglas, Carolynn Lyle, Stephanie Gravitz, Terra Hiller, Ann Z Garcia, Alicia K Cupelo, Judy L Oakes; <u>National Jewish Health|St. Joseph Hospital</u> -James Finigan, Christine Griesmer, Cole Waliczek

MICHIGAN Clinical Center: University of Michigan Medical Center -Robert C. Hyzy\*, Pauline K. Park\*, Kristine Nelson, Norman Olbrich, Stephen Kay; Henry Ford Health System -Namita Jayaprakash, Emanuel P Rivers, Jennifer Swiderek, Jasreen Kaur Gill, Sheri Renaud, Ariella Hodari Gupta, Jacqueline Day, Anja Kathrina Jaehne, Aaron Cook, Jayna Gardner-Gray; Sinai Grace Hospital -Robert Sherwin, James Wooden, Thomas Mazzocco, Jacob Winkel; Detroit Receiving Hospital & Harper University Hospital -Robert Sherwin, Thomas Mazzocco, Theodore Falcon, Jeffrey Harrison; FUNCTION Group - Lee Kamphuis, Steve Vaughn, Sarah Seelye, Stacy Anderson, Taylor Bernstein, Aissa Cabrales, Jennifer Cano, Emily DelMonico, Dana Horowitz, Peggy Korpela, Max Monahan, Tiffany Lee, Jessie Milne, Stephanie Ortiz Chavez, Marylena Rouse, Melanie Vandersluis

MONTEFIORE-SINAI Clinical Center: Montefiore Medical Center - Michelle Gong, Aluko Hope, Omowunmi Amosu, Hiwet Tzehaie, Sabah Boujid, Martha Torres; Mt. Sinai - Lynne D. Richardson, Kusum Mathews, Sam Acquah, Patrick Maher, Neha Goel, George Loo; Montefiore Medical Center - Weiler - Tina Chen, Rahul Nair, Brenda Lopez, Manuel Hache Marliere, Marjan Islam; University of Arizona - Jarrod Mosier, Cameron Hypes, Ariana Cano, Boris Gilson, Elizabeth Salvaggio Campbell

OHIO Clinical Center: <u>Cleveland Clinic Foundation</u> -Abhijit Duggal\*, Omar Mehkri, Kiran Ashok, Siddharth P. Dugar, Simon Mucha; <u>University of Cincinnati Medical Center</u> -Kristin Hudock, Robert Duncan Hite\*, Harshada More, Hammad Tanzeem, Carrie Keininger

PACIFIC NORTHWEST Clinical Center: Oregon Health and Science University - Catherine L. Hough\*, Kelly Vranas, Akram Khan, Olivia F Krol, Madeline McDougal, Rupali Deshmukh, Zhengchun Luy, Milad Karami Jouzestani, Courtney Maxcy, Efrain Chavez Martinez, Otmar Borchard, Edlyn Lopez, Brennan Baylis; Harborview Medical Center - Nicholas J. Johnson, Bryce R.H. Robinson\*, Stephanie Gundel, Sarah Katsandres, Megan R. Fuentes, Kelsey Jiang, Sarah G. Dean, Sakshi Sehgal

PITTSBURGH Clinical Center: <u>University of Pittsburgh Presbyterian, Magee, Mercy, Shadyside</u> -Donald M Yealy\*, Alexandra Weissman, Sara Di Fore, Sarah McGarry, Tina Vita © 2023 Admon AJ et al. *JAMA Network Open.* 

**SOUTHEAST Clinical Center:** Wake Forest Baptist Health -Jessica Palakshappa, Chad Miller\*, Clark Files\*, Lori Flores, Mary LaRose, Rebecca Overman, Shannon Jones; <u>University of Kentucky</u> -Kirby Mayer, Peter Morris, Jamie Sturgill, Sara N Pasha, Evan Cassity; <u>Medical University of South Carolina</u> -Abbey Grady, Andy Goodwin

**UTAH:** Intermountain Medical Center -Samuel Brown\*, Ithan Peltan, Joseph Bledsoe\*, Jason Jacobs, Karah Imel, Brent Armbruster; <u>Utah - LDS Hospital</u> -Melissa Fergus, Valerie Aston; <u>University of Utah Health Sciences Center</u> -Estelle S Harris, Elizabeth A Middleton, Macy AG Barrios, Lindsey J Waddoups, Lindsey A McGuire

**VANDERBILT Clinical Center:** <u>Vanderbilt University Medical Center</u> -Todd W Rice\*, Wesley H Self\*, Margaret Hays, Sarah Frawley, Jakea Johnson; <u>Duke University Medical Center</u> -John Eppensteiner, Grace Hall, Alexander Limkakeng, Christopher Cox

Clinical Coordinating Center: <u>Massachusetts General Hospital Biostatistics Center (CCC)</u>: B. Taylor Thompson\*, Douglas L Hayden, Nancy Ringwood, Cathryn Oldmixon, Richard Morse, Ariela Muzikansky, Laura Fitzgerald, Samuel Whitaker, Haley Morin, Weixing Huang, Grace Carey

Johns Hopkins Medicine: Roy G Brower, Sarina Sahetya

**National Heart, Lung, and Blood Institute**: Lora Reineck, Neil Aggarwal, Karen Bienstock, Michelle Freemer, Myron Maclawiw, Gail Weinmann

**Protocol Review Committee**: Laurie J Morrison, Mark N Gillespie, Richard J Kryscio, Wojciech Zareba, Anne Rompalo, Michael Boeckh

**Data and Safety Monitoring Board:** Polly Parsons, Jason D Christie, Jesse R Hall, Nicholas J Horton, Laurie S Zoloth, Neal Dickert Jr., Deborah Diercks

\*Clinical Center or CCC Principal Investigator

## The National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network:

Abi Fadel, Francois Aboodi, Michael Acquah, Samuel Adams, Jason Y Aggarwal, Neil Alappan, Narendrakumar Albertson, Timothy E Al-Jaghbeer, Mohammed

Almasri, Eyad Andrews, James S Angus, Derek C Baker, Jason V Baron, Rebecca Baumann, Michael Becker, Torben Biehl, Michelle Bixby, Billie A Bledsoe, Joseph R Bloom, John W Bose, Somnath Boyle, Katherine L Bradley, Patrick Branson, Rich D Brown, Samuel Burnham, Ellen L Calfee, Carolyn Callahan, Sean J Cancelliere. Alessandro

Chen, Peter Chen, Tina Chenoweth, James Choi, Philip

Carson, Shannon

Chang, Steven Y

Chekuri, Sweta

Casey, Jonathan D

Co, Ivan Collins, Sean

Costa Monteiro, Ana Carolina

Couper, Mick
Cox, Christopher
Daich, Jonathan
de Wit, Marjolein
deBoisblanc, Ben P
Dettmer, Matthew R
Dhar, Sanjay
Dillon, David
Doernberg, Sarah

Doshi, Pratik B

Douglas, Ivor S Driver, Brian Dugar, Siddharth P Duggal, Abhijit

Elie, Marie-Carmelle Enfield, Kyle B Eppensteiner, John

Fein, Daniel Filbin, Michael Files, Clark Finigan, James H. Flannery, Alexander H.

Foulkes, Andrea Fowler, Alpha A. Frisch, Adam Fung, Monica Gaillard, John Galbraith, James W

Gandotra, Sheetal Gardner-Gray, Jayna M

Gay, Elizabeth A
Gibbs, Kevin
Gill, Evanpaul
Ginde, Adit
Girard, Timothy D
Go, Pauline H
Goel, Neha N
Goligher, Ewan C
Gomez-Arroyo, Jose
Gong, Michelle Ng
Goodwin, Andrew J
Gordon, Richard D
Grissom, Colin K
Gunnerson, Kyle

Hanane, Tarik Hansen, Christopher K

Han. Jin Ho

Happel, Kyle Harris, Estelle S Haukoos, Jason Hendey, Gregory W Hendrickson, Carolyn M.

Hendrickson, Carol Hibbert, Kathryn A. Hirshberg, Ellie Hite, R. Duncan Hope, Aluko A Hoth, Jason Hou, Peter C Hough, Terri Howrylak, Judie A Huang, David T Hudock, Kristin Huebinger, Ryan Hurst, Gina

Hypes, Cameron D Hyzy, Robert C. Iovine, Nicole Islam, Marjan Israel, Jennifer Iwashyna, Jack Jaffer, Faraz Janssen, William Jayaprakash, Namita

Jia, Shijing

Johnson, Nicholas J

Jolley, Sarah Jones, Alan

Jones, Elizabeth Jones B

Kadl, Alex

Kangelaris, Kirsten N Kashiouris, Markos G Kass, Lawrence E Keller, Marla Khan, Akram Khosravi, Mehdi Khouli, Hassan Kinni, Harish Kiyatkin, Michael E

Knox, Daniel Krishnan, Amita Kurtzman, Nicholas Lammi, Matthew R Lanspa, Michael J

Le, Viet

Leither, Lindsay M Levitt, Joseph L'Heureux, Michael Lim, George

Limkakeng, Alexander

Lin, Michael Y Lindsell, Christopher

Liu, Kathleen Lyn-Kew, Kenneth Lyons, Patrick G Mackay, Fraser C

Maher, Patrick J Mahler, Simon A. Malhotra, Anita

© 2023 Admon AJ et al. JAMA Network Open.

Malley, Brian E
Matthay, Michael A
May, Teresa
Mayer, Katherine
Mayer, Kirby P
McSparron, Jakob I
McVerry, Bryan J.
Miller, Chadwick D
Miller, Stephen
Minear, Steven C
Mireles, Eduardo
Mock, Jason
Mohamed, Amira

Montgomery-Yates, Ashley A

Morris, Peter
Mosier, Jarrod M
Moskowitz, Ari
Moss, Marc
Mucha, Simon R
Munroe, Elizabeth
Nair , Rahul
Nandi, Utsav
Nassisi, Denise
Nkemdirim, William
Norton, Dustin L
O'Gara, Brian
O'Hearn, Daniel J

OMahony, Darragh Shane

Page, David B
Paine, Robert
Park, Pauline K
Pasha, Sara

Patarroyo Aponte, Gabriel D

Patel, Avignat Patel, Bela Peltan, Ithan D. Perman, Sarah

Pflaum-Carlson, Jacqueline

Marie

Phang-Lyn, Simone

Pinto-Plata, Victor

Prekker, Matthew E Puskarich, Mike Qadir, Nida Reddy, Raju M

Rogers, Angela J

Rice, Todd W Richardson, Lynne D. Riker, Richard R Rivers, Emanuel P Robinson, Bryce RH Russell, Derek W. Sahoo, Debasis Sandrock, Christian Sanne, Shane Scheraga, Rachel G Schmidt, Eric

Schmidt, Eric Schooler, Jordan B Schwab, Kristin Self, Wesley H. Semler, Matthew W Sergot, Paulina Shah, Faraaz Shapiro, Nate Shaw, Daniel L Sherwin, Robert Siuba, Matthew

Sjoding, Michael Smithline, Howard Sochor, Mark R Spurzem, John R Srinivasan, Vasisht Steel, Tessa L

Steingrub, Jay S Stenson, Bryan Sterling, Sarah A

Stopyra, Jason

Stubblefield, William-May B.

Sturek, Jeffrey M Sturgill, Jamie L Swiderek, Jennifer Syed, Aamer Talmor, Daniel Tatem, Geneva

Thiruchelvam, Nirosshan

Thompson, Taylor

Thompson Bastin, Melissa L

Tidswell, Mark Torbati, Sam S Trent, Stacy A Trott, Terren

Van der Kloot, Thomas E

Vranas, Kelly C Wang, Bonnie Wang, Ralph Ware, Lorraine

Waters, Christopher M. Weissman, Alexandra J Wick, Katherine D Wilkin, Aimee M

Wilkin, Aimee M Wilson, David M Wilson, Jenny G Wyles, David L Yanta, Joseph H Yealy, Donald M Youngquist, Scott Zaman, Tanzira